

Cardiovascular Drugs market

<https://marketpublishers.com/r/C3F06FFE1B4EN.html>

Date: January 2018

Pages: 93

Price: US\$ 2,750.00 (Single User License)

ID: C3F06FFE1B4EN

Abstracts

Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

Overview: Cardiovascular drugs are agents used for the treatment of diseases associated with the circulatory system, which include blood clots, stroke, coronary artery disease, variation in blood pressure, arrhythmias, high cholesterol, and heart failure. Increasing aging population, increasing prevalence of cardiovascular diseases, high incidence of obesity, and an unhealthy lifestyle are driving the demand for cardiovascular drugs. Complex drug development process and adverse effects of cardiovascular drugs are hampering the growth of the market. There is a constant increase in the incidence of cardiovascular diseases. According to WHO, in 2015, approximately 17.7 million people died due to various cardiovascular diseases. Increase in expenditure for R&D of novel cardiovascular drugs and increased government initiatives to raise the alertness of different types of cardiovascular conditions are expected to drive the market growth. Additionally, variation in lifestyle has increased the prevalence of the obesity, which has further led to the increase in the incidence of cardiovascular disorders globally. Nevertheless, the rigorous regulatory approval process for drugs, high treatment cost, and side effects related to cardiovascular drugs are hindering the progress of the market.

Market Analysis: The global cardiovascular drugs market is estimated to witness a CAGR of 2.8% during the forecast period 2018–2024. The market is analyzed based on two segments: product types and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market

growth.

Product Analysis: Based on types, the market is segmented into anti-hypertensives, anti-hyperlipidemics, anticoagulants, antiarrhythmics, and others. Cardiac glycosides, antianginal drugs, anti-fibrinolytic, and anti-ischemic drugs are the other key product types in the market. The market is dominated by anti-hypertensives.

Key Players: Novartis AG, Sanofi, Bayer AG, Johnson & Johnson, Astra Zeneca PLC, and Pfizer are the key players in the market. The other prominent players in the market include Daiichi Sankyo, Inc., Bristol–Myers Squibb, GlaxoSmithKline plc, United Therapeutics Corp., Sun Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, and Gilead Sciences, Inc.

Competitive Analysis: Mergers & acquisitions, approval of new drugs, and product launch are the primary strategies followed by various players in the market to increase their revenue. In March 2017, Espero Pharmaceuticals, Inc., a privately held company in commercial-stage cardiovascular pharmaceutical and Armetheon, Inc., a private company in late-clinical stage pharmaceutical have planned to merge. J&J, a major company in the cardiovascular drugs market established its footprints in this sector in 2008 with the approval of Xarelto in the US. Currently, in 2016, Xarelto earned revenue of ~\$2.5 billion and is anticipated to rise to ~\$3.5 billion by 2024. In January 2017, J&J acquired Actelion and added Uptravi & Opsumit to its portfolio, which are expected to secure the market leadership of the company. Warfarin by Epocrates, Inc. is struggling to maintain the market share from a stable rivulet of new products such as Xarelto, Pradaxa, Eliquis, and Savaysa.

Benefits: The report provides complete details about the usage and adoption rate of cardiovascular drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
- 1.2 Industry Trends
- 1.3 Total Addressable Market (TAM)

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market (SAM)
 - 3.2.1 Trends of cardiovascular drugs market
- 3.3 Related Markets
 - 3.3.1 Oncology (Cancer) Drugs
 - 3.3.2 Active pharmaceutical ingredients (APIs)
 - 3.3.3 Over the counter drugs (OTC)
 - 3.3.4 Diabetes Drugs

4 MARKET OUTLINE

- 4.1 Cardiovascular Drugs Approved by FDA (2011 – 2016)
- 4.2 Market Segmentation
- 4.3 Porter 5(Five) Forces
- 4.4 PEST Analysis

5 MARKET CHARACTERISTICS

- 5.1 Market Dynamics
 - 5.1.1 Drivers
 - 5.1.1.1 Increasing Aging Population
 - 5.1.1.2 Increasing prevalence of cardiovascular diseases

- 5.1.1.3 High Prevalence of Obesity
- 5.1.1.4 Unhealthy lifestyle
- 5.1.2 Opportunities
 - 5.1.2.1 Increase merger and acquisitions
- 5.1.3 Restraints
 - 5.1.3.1 Complex drug development process
 - 5.1.3.2 Adverse effects of cardiovascular drugs
- 5.1.4 DRO – Impact Analysis
- 5.1.5 Key Stakeholders

6 PRODUCT TYPE: MARKET SIZE AND ANALYSIS

- 6.1 Overview
- 6.2 Anti-Hypertensives
- 6.3 Anti-Hyperlipidemics
- 6.4 Anti-Coagulants
- 6.5 Anti-Arrhythmic
- 6.6 Others

7 REGIONS: MARKET SIZE AND ANALYSIS

- 7.1 Overview
- 7.2 North America
 - 7.2.1 Overview
 - 7.2.2 United States
 - 7.2.3 Canada
- 7.3 Europe
 - 7.3.1 Overview
 - 7.3.2 United Kingdom
 - 7.3.3 Germany
- 7.4 APAC
 - 7.4.1 Overview
 - 7.4.2 India
 - 7.4.3 China
 - 7.4.4 Japan
- 7.5 Rest of the World
 - 7.5.1 Overview
 - 7.5.2 Africa
 - 7.5.3 Brazil

8 COMPETITIVE LANDSCAPE

9 VENDOR PROFILES

9.1 Novartis AG

- 9.1.1 Overview
- 9.1.2 Business Unit
- 9.1.3 Geographic Presence
- 9.1.4 Business Focus
- 9.1.5 SWOT Analysis
- 9.1.6 Business Strategy

9.2 Sanofi

- 9.2.1 Overview
- 9.2.2 Geographic Revenue
- 9.2.3 Business Focus
- 9.2.4 SWOT Analysis
- 9.2.5 Business Strategy

9.3 Bayer AG

- 9.3.1 Overview
- 9.3.2 Business Unit
- 9.3.3 Geographic Presence
- 9.3.4 Business Focus
- 9.3.5 SWOT Analysis
- 9.3.6 Business Strategy

9.4 Johnson & Johnson

- 9.4.1 Overview
- 9.4.2 Business Units
- 9.4.3 Geographic Revenue
- 9.4.4 Business Focus
- 9.4.5 SWOT Analysis
- 9.4.6 Business Strategies

9.5 Astra Zenca PLC.

- 9.5.1 Overview
- 9.5.2 Geographic Presence
- 9.5.3 Business Focus
- 9.5.4 SWOT Analysis
- 9.5.5 Business Strategy

10 COMPANIES TO WATCH FOR

10.1 Daiichi Sankyo, Inc.

10.1.1 Overview

10.1.2 Overview

10.2 Bristol-Myers Squibb

10.2.1 Overview

10.3 GlaxoSmithKline plc

10.3.1 Overview

10.4 United Therapeutics Corp

10.4.1 Overview

10.4.2 Highlights

10.5 Sun Pharmaceuticals.

10.5.1 Overview

10.5.2 Highlights

10.6 Eli Lilly and Company.

10.6.1 Overview

10.7 Takeda Pharmaceutical Co, Ltd

10.7.1 Overview

10.7.2 Highlights:

10.8 Boehringer Ingelheim GmbH

10.8.1 Overview

10.8.2 Highlights:

10.9 Gilead Sciences, Inc

10.9.1 Overview

10.9.2 Highlights:

Annexure

Abbreviations

Tables

Table 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY

Table 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES, 2017–2024
(\$BILLION)

Table 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS, 2017–2024
(\$BILLION)

Table 3 NOVARTIS AG: OFFERINGS

Table 4 NOVARTIS AG: RECENT DEVELOPMENTS

Table 5 SANOFI: OFFERINGS

Table 6 SANOFI: RECENT DEVELOPMENTS

Table 7 BAYER AG: OFFERINGS

Table 8 BAYER AG: RECENT DEVELOPMENTS

Table 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS

Table 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS

Table 11 ASTRA ZENCA PLC: OFFERINGS

Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS

Table 13 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS

Table 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS

Table 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS

Table 16 GLAXOSMITHKLINE PLC.: OVERVIEW

Table 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

Table 18 UNITED THERAPEUTICS CORP.: OVERVIEW

Table 19 SUN PHARMACEUTICALS: OVERVIEW

Table 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

Table 21 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW

Table 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW

Table 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS

Table 24 GILEAD SCIENCES, INC.: OVERVIEW

?

Charts

Chart 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 (\$BILLION)

Chart 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET

Chart 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE, 2017-2024 (\$BILLION)

Chart 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016

Chart 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET

Chart 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET

Chart 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET

Chart 8 MARKET DYNAMICS – DRO ANALYSIS

Chart 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)

Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET

Chart 11 KEY STAKEHOLDERS

Chart 12 CARDIOVASCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION, 2017-2024 (\$BILLION)

- Chart 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$BILLION)
- Chart 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$BILLION)
- Chart 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$BILLION)
- Chart 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$BILLION)
- Chart 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$BILLION)
- Chart 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015)
- Chart 19 CARDIOVASCULAR DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
- Chart 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (\$BILLION)
- Chart 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 (\$BILLION)
- Chart 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014
- Chart 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION, 2017–2023 (\$BILLION)
- Chart 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2023 (\$BILLION)
- Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT
- Chart 26 NOVARTIS AG: BUSINESS UNITS
- Chart 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
- Chart 28 NOVARTIS AG: SWOT ANALYSIS
- Chart 29 SANOFI SA: OVERVIEW SNAPSHOT
- Chart 30 SANOFI SA: SEGMENTATION
- Chart 31 SANOFI SA: GEOGRAPHIC REVENUE
- Chart 32 SANOFI SA: SWOT ANALYSIS
- Chart 33 BAYER AG: OVERVIEW SNAPSHOT
- Chart 34 BAYER AG: BUSINESS UNITS
- Chart 35 BAYER GA: GEOGRAPHICAL PRESENCE
- Chart 36 BAYER AG: SWOT ANALYSIS
- Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
- Chart 38 JOHNSON & JOHNSON: BUSINESS UNITS
- Chart 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE

- Chart 40 JOHNSON & JOHNSON: SWOT ANALYSIS
- Chart 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
- Chart 42 ASTRA ZENCA PLC: BUSINESS UNITS
- Chart 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
- Chart 44 ASTRA ZENCA PLC: SWOT ANALYSIS

I would like to order

Product name: Cardiovascular Drugs market

Product link: <https://marketpublishers.com/r/C3F06FFE1B4EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3F06FFE1B4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970